Zhongzhi Pharmaceutical Holdings (HKSE:03737) Net Income From Continuing Operations : HK$227 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Zhongzhi Pharmaceutical Holdings Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Zhongzhi Pharmaceutical Holdings's net income from continuing operations for the six months ended in Dec. 2023 was HK$43 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was HK$227 Mil.

Zhongzhi Pharmaceutical Holdings Net Income From Continuing Operations Historical Data

The historical data trend for Zhongzhi Pharmaceutical Holdings's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongzhi Pharmaceutical Holdings Net Income From Continuing Operations Chart

Zhongzhi Pharmaceutical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

173.52

198.23

75.69

145.90

227.05

Zhongzhi Pharmaceutical Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-22.46	111.84	39.35	183.56	43.49

Zhongzhi Pharmaceutical Holdings Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$227 Mil.

Zhongzhi Pharmaceutical Holdings (HKSE:03737) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhongzhi Pharmaceutical Holdings Ltd (HKSE:03737) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No. 3 Kangtai Road South, Torch Development Zone, Guangdong Province, Zhongshan, CHN

Website

https://www.zeus.cn

Zhongzhi Pharmaceutical Holdings Ltd is engaged in the business of manufacturing and selling pharmaceutical products. The group's operations can be divided into three segments, namely Pharmaceutical manufacturing, Operation of chain pharmacies, and Operation of online pharmacies in Zhongshan in the Guangdong province, the PRC. In the Pharmaceutical manufacturing segment, the company is engaged in the research and development, manufacturing and sale of Chinese patent medicines. In the Operation of chain pharmacies segment, the firm operates chain pharmacies in Zhongshan under the brand Zeus for the sale of pharmaceutical products. The Operation of online pharmacies segment sells medicines online. It derives a majority of its revenue from the PRC.

Zhongzhi Pharmaceutical Holdings (HKSE:03737) Headlines

No Headlines